Business
Bionano Reports First Quarter 2026 Results and Provides a Business Update
Conference call today, May 13, 2026, at 4:30 PM ETSAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community," commented Al Luderer, Ph.D., chairman and interim chief executive
About this update from Bionano Genomics, Inc.
[{"type":"image","alt":"Bionano Genomics","displaySize":"","headline":null,"caption":"Bionano Genomics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BL0NoL0PFOcUTHrfwl5LaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1/https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1","width":300,"height":61},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/BL0NoL0PFOcUTHrfwl5LaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1/https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1","width":300,"height":61}},"lazy":false},{"type":"text","content":"Conference call today, May 13, 2026, at 4:30 PM ET","length":50,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026.","length":158,"tagName":"p"},{"type":"text","content":""The Bionano business is healthy, with first quarter results reflecting the continued engagement of our installed base and positive utilization trends across our optical genome mapping (OGM) and VIA software user community," commented Al Luderer, Ph.D., chairman and interim chief executive officer of Bionano. "The evidence base supporting OGM continues to expand across hematologic malignancies, constitutional genetics, and cell and gene therapy applications, and we are seeing global broad-based adoption at leading institutions. We remain convinced that OGM is on a clear and accelerating path to becoming the standard for comprehensive, genome-wide structural variant analysis. Equally important, we are closing in on a meaningful balance sheet milestone - the expected retirement of our secured convertible debt - which will further strengthen our financial position and allow us to direct future capital towards growing our business.”","length":957,"tagName":"p"},{"type":"text","content":"Q1 2026 Financial Results","length":25,"tagName":"p"},{"type":"text","content":"For the three-month period ended March 31, 2026, as compared to the same period of 2025:","length":88,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported total revenue of $6.7 million, representing ...